April 20, 2018
A California federal judge Thursday nixed a False Claims Act suit accusing Johnson & Johnson subsidiary Janssen Pharmaceutical NV of using unlawful marketing practices to boost off-label sales of its opioid prescription drugs, saying a change of the pseudonym for the whistleblower who filed the suit violated the FCA's first-to-file doctrine.
March 20, 2018
A former Janssen Pharmaceutica NV sales representative who claims the drugmaker overcharged the government, offered kickbacks and marketed drugs off-label on Monday asked a California federal judge to keep the suit alive, rebuffing the company's arguments that she lacked corroboration and forfeited her right to sue by changing her alias.